SCHEMBL5134747

SCHEMBL5134747

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(S)cc1)Cc1ccc(OC(F)F)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
TSHR P16473 4/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
BACE1 P56817 3/20 0.32
CTSD P07339 1/20 0.32
BACE2 Q9Y5Z0 1/20 0.32
CRHR1 P34998 2/20 0.32
PDE4B Q07343 2/20 0.31
CASR P41180 1/20 0.31
PPARG P37231 1/20 0.31
PPARA Q07869 1/20 0.31
GRM2 Q14416 3/20 0.31
CYP3A4 P08684 2/20 0.31
KCNH2 Q12809 1/20 0.31
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648891 0.95 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135869 0.93 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL648409 0.93 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL1915545 0.92 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL649513 0.91 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135223 0.89 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650869 0.89 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650095 0.88 C5AR1 (0.39) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL648764 0.88 C5AR1 (0.40) C5AR1TSHRBACE1CRHR1
SCHEMBL648305 0.88 C5AR1 (0.41) C5AR1TSHRALDH1A1CRHR1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed